Minorities' Diminished Psychedelic Returns: Income and Educations Impact on Whites, Blacks, Hispanics, and Asians.
Journal of Racial and Ethnic Health Disparities June 1, 2025 DOI: 10.1007/s40615-024-02023-y (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Observational cohort Peer reviewed |
|---|---|
| Sample size | 458,372 |
| Population | US adults aged 18 and older from the National Survey of Drug Use (2008-2019) |
| Keywords | Racial inequality Ethnicity Mental health Race Psychedelics hallucinogens Racial bias Entheogens Psychoactive drugs Emotional health Mental wellness Socioeconom |
| Citations | 19 |
| Key findings | After controlling for socioeconomic status, psychedelic use is not associated with lower psychological distress for Black and Hispanic individuals, while it remains associated with lower distress for white individuals, and for Asians with higher education and income some psychedelic use is linked to increased distress. |
Abstract
Growing evidence suggests that the race and ethnic minority population may experience fewer protective effects of psychedelics on mental health. The minority diminished psychedelic returns theory proposes that racism, manifested in socioeconomic inequality, could partially account for the smaller health gains observed. Therefore, it is important to investigate whether socioeconomic inequality reduces the impact of psychedelics on health outcomes for minority populations. Additionally, despite having higher socioeconomic status, it remains unclear whether psychedelic use among minorities is associated with the same level of health benefits as observed in non-Hispanic whites. This study utilizes data from the National Survey of Drug Use (N = 2008 to 2019), which involved 458,372 participants aged 18 and above. The objective is to examine the impact of various psychedelics (MDMA, psilocybin, DMT, ayahuasca, peyote/mescaline, and LSD), as well as lifetime classic psychedelics use (LCPU), on psychological distress in the past month, taking into account socioeconomic factors (education level and family income) and race/ethnic differences (White, Black, Hispanic, and Asian). The analysis employed a series of nested ordinary least-square regression models using Stata 18. The results indicate that, after controlling for socioeconomic status, there is no association between Black and Hispanic psychedelic use and distress. However, white psychedelic use remains associated with lower levels of distress. Additionally, despite having higher levels of education and income, psychedelic use among minority groups does not appear to be linked to reduced stress. In fact, for Asians with higher education and income, certain psychedelic use is associated with increased distress.
Citations in the library
Cited by 19
- Distinctive But Not Exceptional: The Risks of Psychedelic Ethical Exceptionalism. The American Journal of Bioethics 2025
- Association between lifetime hallucinogen use and psychological distress varies by sexual identity in a nationally representative sample Journal of Psychopharmacology September 23, 2024
- Unequal representation? A cross-sectional analysis of age, sex, race, and ethnicity in clinical trials of classic psychedelics Journal of Psychopharmacology July 11, 2025
- Race and Gender Differences in the Moderating Relationship of Psychedelics on Stigma and Distress Psychedelic Medicine April 22, 2025
- Religious Social Integration, Psychedelics, and Psychological Distress. Journal of Psychoactive Drugs November 7, 2024
and 14 more in the library
Cites 43
- Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial Journal of Psychopharmacology November 30, 2016
- Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder JAMA Psychiatry November 4, 2020
- Psychedelics Promote Structural and Functional Neural Plasticity Cell Reports June 1, 2018
- MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. Nature Medicine June 1, 2021
- Quality of Acute Psychedelic Experience Predicts Therapeutic Efficacy of Psilocybin for Treatment-Resistant Depression Frontiers in Pharmacology January 17, 2018
and 38 more in the library